West Pharmaceutical Services (WST) Profit After Tax (2009 - 2026)

West Pharmaceutical Services has disclosed Profit After Tax across 18 years of filings, most recently posting $138.8 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at $138.8 million, up 54.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $542.7 million (up 16.16% YoY), and the FY2025 annual result was $493.7 million, changed 0.2% from the prior year.
• Profit After Tax came in at $138.8 million for Q1 2026 at West Pharmaceutical Services, up from $132.1 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $188.5 million in Q2 2022 to a low of $89.8 million in Q1 2025.
• The 5-year median for Profit After Tax is $136.0 million (2024), against an average of $135.6 million.
• Across the five-year window, Profit After Tax sank 31.32% in 2022 and jumped 54.57% in 2026, its largest moves.
• West Pharmaceutical Services' Profit After Tax stood at $103.0 million in 2022, then jumped by 33.01% to $137.0 million in 2023, then decreased by 5.04% to $130.1 million in 2024, then climbed by 1.54% to $132.1 million in 2025, then grew by 5.07% to $138.8 million in 2026.
• The last three Profit After Tax figures came in at $138.8 million (Q1 2026), $132.1 million (Q4 2025), and $140.0 million (Q3 2025), per Business Quant data.